Research programme: CNS disease therapies - ImClone/Neurome
Latest Information Update: 27 Mar 2009
At a glance
- Originator ImClone Systems; Neurome
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 28 Sep 2004 Preclinical trials in CNS disorders in USA (unspecified route)